Compare Byrna Technologies Inc (BYRN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs GeneDx Holdings Corp — how do they compare? Byrna Technologies Inc trades at $4.24 (market cap $106.74M), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: GeneDx Holdings Corp is far larger — about 22.9× Byrna Technologies Inc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BYRN | WGS | |
|---|---|---|
Market Cap | $106.74M | $2.44B |
Sector | Technology | Technology |
52-Week High | $27.63 | $167.51 |
52-Week Low | $3.18 | $34.51 |
Enterprise Value | $98.35M | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $4.32, down 10.93% amid weak Q2 2026 results, with revenue declining 42.5% and a significant EPS miss. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with negative net income and ROE. Recent management changes and marketing initiatives aim to address sales challenges, while an ongoing legal investigation adds uncertainty.
The outlook is mixed; analyst consensus is 71% buy with potential from new leadership and product expansion, but execution risk is high given profit declines and competitive pressures. Investors should weigh turnaround efforts against persistent operational weaknesses and legal overhangs for near-term volatility.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
